{
    "clinical_study": {
        "@rank": "46846", 
        "arm_group": [
            {
                "arm_group_label": "5 consecutive days bimonthly", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oprozomib administered orally, once daily, on Days 1-5 of a 14-day cycle in combination with 20 mg of dexamethasone on Days 1, 2, 8, and 9. Treatment will be administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason."
            }, 
            {
                "arm_group_label": "2 consecutive days weekly", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oprozomib administered orally, once daily, on Days 1, 2, 8, and 9 of a 14-day cycle in combination with 20 mg of dexamethasone on Days 1, 2, 8, and 9. Treatment will be administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives are as follows:\n\n      Phase 1b:\n\n        -  To determine the maximum tolerated dose (MTD) of oprozomib given orally, once daily, on\n           2 different schedules.\n\n        -  To evaluate safety and tolerability\n\n      Phase 2:\n\n        -  To estimate the overall response rate (ORR).\n\n        -  To evaluate safety and tolerability"
        }, 
        "brief_title": "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Diagnosis of multiple myeloma with measureable disease\n\n          -  Patients requiring therapy who have relapsed and/or are refractory to their last\n             therapy and have been treated with at least 1, but not more than 5 lines of multiple\n             myeloma therapy.\n\n        EXCLUSION CRITERIA:\n\n          -  Radiation therapy within 2 weeks prior to first dose.  Localized radiation therapy\n             within 1 week prior to first dose.\n\n          -  Immunotherapy/standard myeloma therapy within 2 weeks; prior stem cell transplant\n             (SCT) therapy (autologous SCT within the prior 8 weeks; allogeneic SCT within the\n             prior 16 weeks)\n\n          -  Participation in an investigational therapeutic study within 3 weeks prior to first\n             dose\n\n          -  Patients who failed to respond to carfilzomib treatment defined as not having\n             achieved \u2265 PR during therapy\n\n          -  Carfilzomib exposure within 6 months prior to first dose\n\n          -  Prior oprozomib exposure\n\n          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the\n             first dose\n\n          -  Other malignancy within the past 3 years with the exception of adequately treated\n             basal cell carcinoma of the skin, squamous cell skin cancer, thyroid cancer,\n             carcinoma in situ of the cervix, carcinoma in situ of the breast, prostate cancer of\n             Gleason Score 6 or less with stable prostate specific antigen levels, or cancer\n             considered cured by surgical resection.\n\n          -  Plasma cell leukemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832727", 
            "org_study_id": "2012-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "5 consecutive days bimonthly", 
                    "2 consecutive days weekly"
                ], 
                "description": "Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 or on Days 1, 2, 8, and 9 of the 14-day treatment cycle.", 
                "intervention_name": "Oprozomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "OPZ", 
                    "ONX 0912", 
                    "oprozomib tablets"
                ]
            }, 
            {
                "arm_group_label": [
                    "5 consecutive days bimonthly", 
                    "2 consecutive days weekly"
                ], 
                "description": "Dexamethasone 20 mg will be taken on Days 1, 2, 8, and 9", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "multiple myeloma", 
            "oprozomib", 
            "OPZ", 
            "ONX 0912", 
            "Onyx", 
            "proteasome inhibitor", 
            "oprozomib tablets"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Division of Hematology/ Oncology, UNC at Chapel Hill"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Gabrail Cancer Center Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Froedtert Hospital and the Medical College of Wisconsin"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "877-669-9121"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1b- Determine the Maximum Tolerated Dose (MTD) of oprozomib given orally, once daily, on 2 different schedules:  5 consecutive days every 14 days (bimonthly) or 2 consecutive days every 7 days (weekly) for a 14-day treatment cycle, both schedules given in combination with dexamethasone", 
                "measure": "Determine the MTD (Phase 1b)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks to 18 months"
            }, 
            {
                "description": "Phase 2 - Estimate the ORR", 
                "measure": "Determine the ORR (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks - 18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832727"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}